Payment overview · 2025
General Payments
$983.04
62 reported records · 16 companies
Healthcare provider profile · identity verified
Jack-Ky Wang, MD
Allopathic & Osteopathic Physicians|Family Medicine · BELOIT, WI · NPI 1093744617
Verified facts
What the public records show
CMS Open Payments records show Jack-Ky Wang, MD received $983.04 in general payments during 2025 across 62 reported records.
PFIZER INC. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $239.25 | 24.3% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.96 | 19.8% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $146.67 | 14.9% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.27 | 10.5% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $57.68 | 5.9% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $51.84 | 5.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.78 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.73 | 2.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.95 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.98 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.76 | 1.9% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $16.90 | 1.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.38 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.56 | 1.5% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.86 | 1.4% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.47 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $983.04 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $239.25 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $154.12 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $130.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.82 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $83.95 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.33 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $57.68 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $51.84 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.86 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.51 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 293 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 321 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
321 | 68 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
321 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 891 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 716 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 473 | 134 |
| Losartan Potassium | Losartan Potassium | 416 | 113 |
| Omeprazole | Omeprazole | 388 | 112 |
| Metoprolol Tartrate | Metoprolol Tartrate | 359 | 84 |
| Furosemide | Furosemide | 357 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 91 |
| Lisinopril | Lisinopril | 324 | 87 |
| Jardiance | Empagliflozin | 321 | 68 |
| Eliquis | Apixaban | 293 | 53 |
| Gabapentin | Gabapentin | 268 | 69 |
| Metformin Hcl | Metformin Hcl | 251 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 58 |
| Potassium Chloride | Potassium Chloride | 208 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 198 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 191 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 57 |
| Trazodone Hcl | Trazodone Hcl | 164 | 36 |
| Finasteride | Finasteride | 162 | 41 |
| Ozempic | Semaglutide | 155 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 39 |
| Simvastatin | Simvastatin | 135 | 31 |
| Glimepiride | Glimepiride | 133 | 37 |
| Tramadol Hcl | Tramadol Hcl | 128 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 38 |
| Sertraline Hcl | Sertraline Hcl | 119 | 26 |
| Celecoxib | Celecoxib | 106 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 29 |
| Warfarin Sodium | Warfarin Sodium | 103 | 14 |
| Allopurinol | Allopurinol | 101 | 30 |
| Ezetimibe | Ezetimibe | 98 | 22 |
| Metolazone | Metolazone | 98 | 18 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 27 |
| Montelukast Sodium | Montelukast Sodium | 88 | 24 |
| Mounjaro | Tirzepatide | 88 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 20 |
| Spironolactone | Spironolactone | 82 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 42 |
| Methylprednisolone | Methylprednisolone | 75 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 17 |
| Atenolol | Atenolol | 72 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 14 |
| Azithromycin | Azithromycin | 70 | 52 |
| Carvedilol | Carvedilol | 69 | 20 |
| Clonidine Hcl | Clonidine Hcl | 69 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 19 |
| Xarelto | Rivaroxaban | 69 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 68 | 20 |
| Alprazolam | Alprazolam | 67 | 21 |
| Famotidine | Famotidine | 67 | 22 |
| Mirtazapine | Mirtazapine | 67 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 49 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Propranolol Hcl | Propranolol Hcl | 57 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Prednisone | Prednisone | 55 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 13 |
| Linzess | Linaclotide | 54 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 24 |
| Pregabalin | Pregabalin | 52 | 12 |
| Lovastatin | Lovastatin | 50 | 13 |
| Benazepril Hcl | Benazepril Hcl | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 12 |
| Enalapril Maleate | Enalapril Maleate | 42 | 12 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Nystatin | Nystatin | 39 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 14 |
| Valacyclovir | Valacyclovir Hcl | 32 | 13 |
| Glipizide | Glipizide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Topiramate | Topiramate | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Nystop | Nystatin | 25 | 12 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Lactulose | Lactulose | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Klayesta | Nystatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 14 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $983.04 · 62 records | PFIZER INC. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EUFLEXXA, EXOGEN ULTRASOUND BONE HEALING SYSTEM, JARDIANCE, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SPRAVATO, VRAYLAR, Wegovy, XIFAXAN, XTAMPZA, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error